NASDAQ:EXEL

Exelixis Stock Insider Trading

Healthcare > Biotechnology

Buy EXEL

*Your capital is at risk

$51.60

+3.06 (+6.30%)

At Close: Jun 03, 2026

Exelixis Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -51.01. In total, the insiders bought 3.36M and sold 3.08M EXEL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-51.01
● Buy	3.36M shares
● Sell	3.08M shares
45% Buy Activity Moderate Positive Correlation
Sell Signal High Confidence Feb 18, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -51.01. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 17, 2026 Buy	Common Stock M-Exempt	Smith Julie Director	Director	42 422 Value: $771.7K
Feb 17, 2026 Buy	Option (right to buy) M-Exempt	Smith Julie Director	Director	42 422 Value: $771.7K
Feb 17, 2026 Sell	Common Stock G-Gift	Morrissey Michael President And CEO	CEO / President	250 736 Value: $0
Feb 17, 2026 Sell	Common Stock S-Sale	Haley Patrick J. EVP, Commercial	Officer	3 036 Value: $133.1K
Feb 17, 2026 Sell	Common Stock S-Sale	Senner Christopher J. EVP And CFO	C-Suite Officer	30 617 Value: $1.34M
Feb 17, 2026 Sell	Common Stock S-Sale	Haley Patrick J. EVP, Commercial	Officer	64 778 Value: $2.82M
Feb 17, 2026 Buy	Common Stock G-Gift	Morrissey Michael President And CEO	CEO / President	250 736 Value: $11.1M
Feb 15, 2026 Sell	Common Stock F-InKind	Hefti Brenda SVP And General Counsel	Officer	5 430 Value: $238.5K
Feb 15, 2026 Sell	Common Stock F-InKind	Aftab Dana EVP, Research And Development	Officer	12 720 Value: $558.7K
Feb 15, 2026 Sell	Common Stock F-InKind	Aftab Dana EVP, Research And Development	Officer	26 485 Value: $1.16M
Feb 15, 2026 Sell	Common Stock F-InKind	Morrissey Michael President And CEO	CEO / President	120 390 Value: $5.29M
Feb 15, 2026 Sell	Common Stock F-InKind	Senner Christopher J. EVP And CFO	C-Suite Officer	35 870 Value: $1.58M
Feb 15, 2026 Sell	Common Stock F-InKind	Haley Patrick J. EVP, Commercial	Officer	31 483 Value: $1.38M
Feb 13, 2026 Buy	Option (right to buy) M-Exempt	Oliver Bob Director	Director	9 088 Value: $175.2K
Feb 13, 2026 Sell	Common Stock S-Sale	Oliver Bob Director	Director	21 162 Value: $929.0K
Feb 13, 2026 Sell	Common Stock S-Sale	Oliver Bob Director	Director	9 088 Value: $396.3K
Feb 13, 2026 Buy	Common Stock M-Exempt	Oliver Bob Director	Director	9 088 Value: $175.2K
Feb 13, 2026 Sell	Common Stock S-Sale	Eckhardt Sue Gail Director	Director	3 856 Value: $168.9K
Feb 13, 2026 Buy	Option (right to buy) M-Exempt	Morrissey Michael President And CEO	CEO / President	494 700 Value: $10.5M
Feb 13, 2026 Sell	Common Stock F-InKind	Morrissey Michael President And CEO	CEO / President	369 606 Value: $16.2M
Feb 13, 2026 Sell	Common Stock S-Sale	Senner Christopher J. EVP And CFO	C-Suite Officer	34 278 Value: $1.47M
Feb 13, 2026 Buy	Common Stock M-Exempt	Morrissey Michael President And CEO	CEO / President	494 700 Value: $10.5M
Jan 15, 2026 Sell	Common Stock F-InKind	Senner Christopher J. EVP And CFO	C-Suite Officer	40 459 Value: $1.83M
Jan 15, 2026 Sell	Common Stock F-InKind	Haley Patrick J. EVP, Commercial	Officer	32 332 Value: $1.46M
Jan 15, 2026 Sell	Common Stock F-InKind	Aftab Dana EVP, Research And Development	Officer	27 254 Value: $1.23M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT EXELIXIS

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CA...

Read Full Profile Here